Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Multiple sclerosis and neuroimmunology

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.

Tania Kümpfel; Katrin Giglhuber; Orhan Aktas; Ilya Ayzenberg; Judith Bellmann-Strobl; Vivien Häußler; Joachim Havla; Kerstin Hellwig; Martin W Hümmert; Sven Jarius; Ingo Kleiter; Luisa Klotz; Markus Krumbholz; Friedemann Paul; Marius Ringelstein; Klemens Ruprecht; Makbule Senel; Jan-Patrick Stellmann; Florian Then Bergh; Corinna Trebst; Hayrettin Tumani; Clemens Warnke; Brigitte Wildemann; Achim Berthele; Neuromyelitis Optica Study Group (NEMOS)

Originally published in Journal of neurology · 2023-09-07

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that causes severe inflammation in the central nervous system (CNS), primarily affecting the optic nerves, spinal cord, and brainstem. The pillars of NMOSD therapy are attack treatment and attack prevention to minimize the accrual of neurological disability. Aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) are a diagnostic marker of the disease and play a significant role in its pathogenicity. Recent advances in understanding NMOSD have led to the development of new therapies and the completion of randomized controlled trials. Four preventive immunotherapies have now been approved for AQP4-IgG-positive NMOSD in many regions of the world: eculizumab, ravulizumab - most recently-, inebilizumab, and satralizumab. These new drugs may potentially substitute rituximab and classical immunosuppressive therapies, which were as yet the mainstay of treatment for both, AQP4-IgG-positive and -negative NMOSD.

Methods

The initial version of this manuscript was prepared by TK, KG, and AB as part of a core working group of 24 German neurologists from 15 NEMOS centers, all specialized in the management of NMOSD, through discussions at NEMOS meetings and sessions. The manuscript was then reviewed and edited by representatives of the group, and specific recommendations were developed by the core group through the Delphi method [159]. The revised version of the manuscript, including the recommendations, was distributed to all members of NEMOS (see Appendix) for further feedback and revisions.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?